ImmunoGen Message Board - Msg: 32053005

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	3/3/2019 4:09:01 PM
	Read Replies (1) of 5665

If you're an investor in IMGN, don't panic and sell at these prices. Top line results may have been factual, but they weren't well presented as no commitment was taken to gaining approval in the sub group that certainly were seeing a substantial benefit. Medically knowledgeable investors, which excludes me, are quite certain of approval based on the subset, the question is whether the FDA will require more data, and thus another trial, or if they'll approve with a more restricted label. In that the FDA is supposed to be more dynamic, and the survival benefit is clear, hopefully a BLA will be accepted on that basis and should gain approval. If I hadn't promised my wife that I'd buy no more, I'd be purchasing at this time. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next